Keywords: Merck & Co, Daxas, COPD, UK, NICE, Clinical trial, Cost-effectiveness

NICE wants more data on Daxas

Article | 08 December 2011

Print This

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today issued final draft guidance on the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in